跳至主要内容
临床试验/TCTR20201227001
TCTR20201227001Enrolling By Invitation2 期

Efficacy and safety of a hair growth promoting product containing topical 1% melatonin for treatment of androgenetic alopecia in women: A randomized double-blind trial

Faculty of Medicine, Thammasat University (Rungsit campus)0 个研究点目标入组 100 人开始时间: 2020年12月27日最近更新:
适应症

试验速览

阶段
2 期
状态
Enrolling By Invitation
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 Years 至 65 Years(—)
性别
Female

入选标准

  • 1. Female pattern hair loss (Androgenetic alopecia), Type II - V of Sinclair scale
  • 2. Healthy status

排除标准

  • 1. No topical treatment include minoxidil for AGA within 6 months
  • 2. No topical herb solution for hair growth within 6 months
  • 3. No systemic treatment for AGA within 6 months. For example, oral contraceptive drug, finasteride, dutasteride, spironolactone
  • 4. No history of chemotherapy and radiation within 1 year prior to the clinical trials
  • 5. No topical steroid that apply a scalp at least 14 days within 3 months prior to the trials
  • 6. No pregnancy and breastfeeding status
  • 7. No history of hypersensitivity to melatonin and minoxidil
  • 8. No multiple comorbidities

研究者

发起方
Faculty of Medicine, Thammasat University (Rungsit campus)

相似试验